EDDA Technology

The firm develops and markets the IQQA® platform, an end-to-end system that assists clinicians throughout the entire patient care cycle. This cycle includes pre-surgical planning and simulation, intra-operative guidance and monitoring, and post-operative evaluation and follow-up. The business model appears to be centered on selling its software and hardware solutions to healthcare providers. EDDA Technology serves hospitals and clinical departments, with notable clients including the Mayo Clinic in the US, and several prominent hospitals in China. The company is headquartered in Princeton, New Jersey, and operates subsidiaries in Shanghai and Suzhou, China.

The core product, the IQQA® platform, is a suite of software and systems designed to create patient-specific, quantitative 3D models from multimodality imaging data like CT and MR scans. Key features include highly automated volumetric organ and lesion segmentation, treatment simulation with tools like a virtual knife, and real-time, interactive navigation during surgical procedures. This technology aims to improve the precision of minimally invasive and robotic surgeries by allowing surgeons to visualize and quantitatively reference anatomy in 3D during an operation. The platform has received multiple regulatory clearances from the U.S. Food and Drug Administration (FDA) and China's NMPA. For instance, IQQA®-Chest was cleared by the FDA in 2005, IQQA®-BodyImaging received clearance in 2014, and IQQA®-Guide for intra-operative navigation was cleared in 2015. In April 2021, the company announced a significant financing round of $150 million, led by Softbank Vision Fund 2, with participation from OrbiMed and others, to advance its intelligent robotic solutions for precision surgery.